Meet the six startups that will be working with Shell and Greentown Labs for the next six months. Photo via Greentown

Greentown Labs has named the six participating climatetech startups for an accelerator for a global energy leader.

Shell and Greentown Labs announced the cohort for Greentown Go Make 2023 — a program designed to accelerate partnerships between startups and corporates to advance carbon utilization, storage, and traceability solutions with manufacturing in mind. Shell, which invests in net-zero and carbon-removal technologies, is hoping to strategically align with startups within carbon utilization, storage, and traceability across the energy transition spectrum.

“At Greentown Labs we recognize and appreciate the role energy incumbents must play in the energy transition, and we’re eager to facilitate meaningful partnerships between these impressive startups and Shell—not only to advance these technologies but also to help Shell achieve its sustainability goals,” Kevin Knobloch, CEO and President of Greentown Labs, says in a news release. “We know carbon utilization, storage, and traceability will play a critical role in our collective efforts to reach net-zero, and we’re enthusiastic about the potential impact these companies can have in that work.”

The cohort, selected from 110 applications, is co-located at Greentown's Houston and Somerville, Massachusetts, locations and includes:

  • Portland-based Caravel Bio is developing a novel synthetic biology platform that uses microbial spores and enzymes to create catalysts that are long-lasting and can withstand extreme conditions and environments.
  • Circularise, which is based in the Netherlands, is developing a blockchain platform that provides digital product passports for end-to-end traceability and secure data exchange for industrial supply chains.
  • Corumat, based in Washington, converts organic waste into high-performance, insulating, greaseproof, and biodegradable packaging materials.
  • Cambridge, Massachusetts-headquartered Lydian develops a fully electrified reactor that can convert a variety of gaseous, non-fossil feedstocks into pure syngas with high efficiency.
  • Maple Materials from Richmond, California is developing a low-cost electrolysis process to split carbon dioxide into graphite and oxygen.
  • Ontario, Canada-founded Universal Matter develops a proprietary Flash Joule Heating process that converts carbon waste into high-value and high-performance graphene materials to efficiently create sustainable circular economies.

The program, which includes $15,000 in non-dilutive stipend funding for each company, will work closely with Shell and Greentown over six months via mentorship, networking opportunities, educational workshops, and partnership-focused programming to support collaboration. Go Make 2023 concludes with a showcase event on March 27 at Greentown Labs’ Houston location.

This week, Shell announced another accelerator cohort it's participating in. The Shell GameChanger Accelerator, a partnership with the U.S. Department of Energy’s National Renewable Energy Laboratory (NREL), named four West Coast climatetech companies: DTE Materials, Hexas Biomass, Invizyne Technologies, and ZILA BioWorks. The program provides early-stage cleantech startups with access to experts and facilities to reduce technology development risk and accelerate commercialization of new cleaner technologies.

“Tackling the climate challenge requires multifaceted solutions. At Shell, we believe technology that removes carbon dioxide from the atmosphere will be essential for lowering emissions from energy and chemical products,” Yesim Jonsson, Shell’s GCxN program manager, says in a statement. “The companies in GCxN's sixth cohort embody these objectives and have the potential to usher in a more sustainable future.”

------

This article originally ran on EnergyCapital.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”